Sun Pharmaceutical's US subsidiary has received US FDA approval for generic Casodex, bicalutamide tablets.
These bicalutamide tablets, USP 50 mg are therapeutically equivalent to Casodex tablets from AstraZeneca. Casodex tablets have annual sales of approximately USD 314 million in the US.
Bicalutamide tablets are an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate.